Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for the initial treatment of patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The aim of our study is to evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the metastatic setting.
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer / Visani, L., Livi, L., Ratosa, I., Orazem, M., Ribnikar, D., Saieva, C., Becherini, C., Salvestrini, V., Scoccimarro, E., Valzano, M., Cerbai, C., Desideri, I., Bernini, M., Orzalesi, L., Nori, J., Bianchi, S., Morandi, A., Meattini, I.. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - 177:(2022), pp. 40-45. [10.1016/j.radonc.2022.10.023]
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
Bernini, Marco;
2022
Abstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for the initial treatment of patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The aim of our study is to evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the metastatic setting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Visani et al Radiotherapy and Oncology 2022 copia.pdf
Accesso riservato
Dimensione
472.58 kB
Formato
Adobe PDF
|
472.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
